**Supplemental Tables:**

**Supplemental Table 1.** Association of **Current Use** of Individual ARVs with LV **Function** Measures in Models Mutually Adjusting for All Other ARVs

**Supplemental Table 2.** Association of **Cumulative Duration** of Individual ARVs with LV **Function** Measures in Models Mutually Adjusting for all Other ARVs

**Supplemental Table 3.** Association of **Current Use** of Individual ARVs with Primary LV **Structure** Measures in Models Mutually Adjusting for All Other ARVs

**Supplemental Table 4.** Association of **Current Use** of Individual ARVs with Secondary LV **Structure** Measures in Models Mutually Adjusting for all Other ARVs

**Supplemental Table 5.** Association of **Cumulative Duration** of Individual ARVs with Primary LV **Structure** Measures in Models Mutually Adjusting for all Other ARVs

**Supplemental Table 6.** Association of **Cumulative Duration** of Individual ARVs with Secondary LV **Structure** Measures in Models Mutually Adjusting for all Other ARVs

**Supplemental Table 1.** Association of Current Use of Individual ARVs with LV Function Measures in Models Mutually Adjusting for All Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART Drug(current use)** | **Ejection Fractionest.1 (se) p-value** | **Contractility est.1 (se) p-value** | **Fractional Shortening est.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC) | 0.01 (0.15) 0.97 | -0.32 (0.17) 0.058 | 0.06 (0.15) 0.68 |
| Abacavir (ABC) | -0.20 (0.14) 0.14 | -0.06 (0.17) 0.72 | -0.25 (0.14) 0.075 |
| Stavudine (d4T) | 0.04 (0.18) 0.84 | 0.01 (0.21) 0.96 | -0.09 (0.19) 0.65 |
| Didanosine (ddI) | 0.12 (0.15) 0.43 | 0.09 (0.19) 0.62 | 0.26 (0.16) 0.11 |
| Emtricitabine (FTC) | -0.17 (0.20) 0.40 | -0.09 (0.27) 0.74 | -0.24 (0.21) 0.25 |
| Tenofovir (TDF) | -0.05 (0.18) 0.79 | -0.14 (0.23) 0.54 | 0.05 (0.19) 0.78 |
| Zidovudine (ZDV) | -0.14 (0.16) 0.38 | 0.20 (0.19) 0.31 | -0.19 (0.16) 0.24 |
|  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV) | 0.08 (0.16) 0.62 | -0.401 (0.20) 0.042 | 0.13 (0.16) 0.43 |
| Nevirapine (NVP) | -0.20 (0.23) 0.40 | 0.029 (0.28) 0.92 | -0.003 (0.24) 0.99 |
|  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV) | 0.32 (0.93) 0.73 | 0.25 (1.03) 0.81 | 1.54 (0.99) 0.12 |
| Atazanavir (ATV) | 0.04 (0.26) 0.89 | -0.26 (0.34) 0.44 | 0.34 (0.26) 0.20 |
| Darunavir (DRV) | 0.34 (0.40) 0.39 | -0.17 (0.48) 0.72 | 0.56 (0.39) 0.16 |
| Lopinavir (LPV/r) | 0.28 (0.14) 0.052 | 0.13 (0.18) 0.46 | 0.29 (0.15) 0.056 |
| Nelfinavir (NFV) | -0.24 (0.21) 0.25 | 0.01 (0.24) 0.98 | 0.07 (0.22) 0.75 |
| Ritonavir (RTV) | 0.43 (0.25) 0.088 | 0.49 (0.33) 0.13 | 0.21 (0.25) 0.40 |
| Saquinavir (SQV) | 0.12 (0.35) 0.73 | 0.22 (0.57) 0.70 | -0.04 (0.37) 0.93 |
|  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL) | -0.22 (0.25) 0.37 | -0.038 (0.30) 0.90 | -0.13 (0.26) 0.62 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.

**Supplemental Table 2.** Association of Cumulative Duration of Individual ARVs with LV Function Measures in Models Mutually Adjusting for all Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART Drug(Duration in years)** | **Ejection Fractionest.1 (se) p-value** | **Contractility est.1 (se) p-value** | **Fractional Shortening est.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC)  | -0.004 (0.02) 0.81 | -0.03 (0.02) 0.20 | 0.002 (0.02) 0.93 |
| Abacavir (ABC)  | -0.02 (0.02) 0.37 | -0.01 (0.03) 0.70 | -0.02 (0.02) 0.37 |
| Stavudine (d4T)  | -0.02 (0.02) 0.28 | -0.04 (0.02) 0.13 | -0.02 (0.02) 0.32 |
| Didanosine (ddI)  | -0.00 (0.02) 0.98 | 0.01 (0.02) 0.79 | 0.02 (0.02) 0.24 |
| Emtricitabine (FTC)  | 0.01 (0.04) 0.85 | 0.003 (0.08) 0.97 | -0.003 (0.04) 0.95 |
| Tenofovir (TDF)  | -0.01 (0.04) 0.89 | -0.04 (0.05) 0.46 | -0.03 (0.04) 0.46 |
| Zidovudine (ZDV)  | -0.03 (0.02) 0.13 | -0.02 (0.02) 0.31 | -0.03 (0.02) 0.11 |
|  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV)  | 0.03 (0.02) 0.21 | -0.03 (0.03) 0.25 | 0.01 (0.02) 0.58 |
| Nevirapine (NVP)  | -0.00 (0.02) 0.99 | -0.01 (0.03) 0.59 | -0.02 (0.02) 0.31 |
|  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV)  | 0.004 (0.07) 0.95 | 0.06 (0.08) 0.45 | 0.05 (0.06) 0.46 |
| Atazanavir (ATV)  | -0.02 (0.05) 0.66 | -0.03 (0.07) 0.69 | 0.03 (0.06) 0.61 |
| Darunavir (DRV)  | 0.11 (0.19) 0.58 | -0.11 (0.21) 0.60 | 0.13 (0.19) 0.48 |
| Indinavir (IDV)  | -0.02 (0.07) 0.73 | -0.03 (0.09) 0.74 | 0.05 (0.07) 0.44 |
| Lopinavir (LPV/r)  | 0.01 (0.03) 0.58 | -0.003 (0.04) 0.93 | 0.01 (0.03) 0.81 |
| Nelfinavir (NFV)  | 0.004 (0.02) 0.82 | 0.003 (0.02) 0.89 | 0.02 (0.02) 0.36 |
| Ritonavir (RTV)  | 0.03 (0.02) 0.15 | 0.02 (0.03) 0.52 | 0.02 (0.02) 0.36 |
| Saquinavir (SQV)  | -0.01 (0.04) 0.71 | 0.04 (0.05) 0.37 | 0.04 (0.04) 0.29 |
|  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL)  | -0.26 (0.24) 0.28 | -0.09 (0.26) 0.73 | -0.31 (0.25) 0.21 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.

**Supplemental Table 3.** Association of Current Use of Individual ARVs with Primary LV Structure Measures in Models Mutually Adjusting for All Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART drug(current use)** | **LV Massest.1 (se) p-value** | **ED Dimensionest.1 (se) p-value** | **ED Wall Thicknessest.1 (se) p-value** | **ES Wall Stressest.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC) | -0.15 (0.15) 0.35 | -0.19 (0.16) 0.23 | -0.07 (0.15) 0.63 | -0.13 (0.18) 0.49 |
| Abacavir (ABC) | -0.01 (0.14) 0.97 | 0.01 (0.15) 0.97 | -0.10 (0.14) 0.47 | 0.29 (0.18) 0.10 |
| Stavudine (d4T) | -0.03 (0.19) 0.89 | 0.06 (0.20) 0.76 | -0.14 (0.18) 0.45 | 0.47 (0.23) 0.040 |
| Didanosine (ddI) | -0.21 (0.16) 0.19 | -0.01 (0.17) 0.93 | -0.04 (0.15) 0.78 | -0.03 (0.20) 0.89 |
| Emtricitabine (FTC) | 0.09 (0.21) 0.68 | -0.21 (0.22) 0.34 | -0.23 (0.20) 0.25 | 0.08 (0.29) 0.80 |
| Tenofovir (TDF) | -0.04 (0.19) 0.82 | 0.13 (0.19) 0.50 | -0.08 (0.18) 0.67 | 0.00 (0.25) 1.00 |
| Zidovudine (ZDV) | 0.16 (0.16) 0.33 | 0.35 (0.17) 0.036 | -0.24 (0.15) 0.12 | 0.60 (0.20) 0.004\* |
|  |  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV) | -0.38 (0.17) 0.023 | -0.24 (0.17) 0.16 | -0.02 (0.16) 0.89 | -0.56 (0.21) 0.007\* |
| Nevirapine (NVP) | 0.16 (0.25) 0.51 | 0.70 (0.26) 0.008\* | 0.12 (0.24) 0.63 | 0.18 (0.30) 0.54 |
|  |  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV) | -0.19 (0.99) 0.85 | -1.42 (1.03) 0.17 | -0.12 (0.95) 0.90 | -2.19 (1.10) 0.048 |
| Atazanavir (ATV) | -0.09 (0.27) 0.73 | -0.28 (0.27) 0.31 | -0.37 (0.25) 0.14 | -0.39 (0.35) 0.27 |
| Darunavir (DRV) | -0.36 (0.42) 0.40 | -0.23 (0.41) 0.59 | -0.15 (0.38) 0.70 | -0.34 (0.51) 0.50 |
| Lopinavir (LPV/r) | 0.15 (0.15) 0.33 | 0.17 (0.16) 0.29 | 0.02 (0.15) 0.91 | -0.25 (0.19) 0.18 |
| Nelfinavir (NFV) | 0.08 (0.22) 0.72 | -0.16 (0.23) 0.48 | -0.003 (0.21) 0.99 | -0.28 (0.25) 0.26 |
| Ritonavir (RTV) | 0.19 (0.28) 0.48 | 0.22 (0.26) 0.40 | 0.38 (0.24) 0.12 | -0.27 (0.34) 0.43 |
| Saquinavir (SQV) | -0.27 (0.37) 0.46 | -0.43 (0.39) 0.27 | -0.15 (0.36) 0.68 | -0.07 (0.62) 0.91 |
|  |  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL) | -0.08 (0.28) 0.78 | -0.06 (0.28) 0.83 | -0.11 (0.25) 0.66 | 0.32 (0.31) 0.30 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.

\* Met criteria for significance after controlling False Discovery Rate (FDR) at 0.10 within each parameter.

**Supplemental Table 4.** Association of Current Use of Individual ARVs with Secondary LV Structure Measures in Models Mutually Adjusting for all Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART Drug(current use)** | **ED Volume  est.1 (se) p-value** | **ES Volume  est.1 (se) p-value** | **Thickness-Dimension Ratio  est.1 (se) p-value** | **ED Septal Thickness  est.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC) | -0.37 (0.15) 0.016 | -0.29 (0.15) 0.047 | 0.06 (0.14) 0.68 | 0.27 (0.14) 0.049 |
| Abacavir (ABC) | 0.18 (0.14) 0.20 | 0.28 (0.14) 0.040 | -0.11 (0.13) 0.40 | -0.10 (0.13) 0.43 |
| Stavudine (d4T) | 0.03 (0.19) 0.86 | 0.01 (0.18) 0.94 | -0.14 (0.17) 0.42 | -0.08 (0.17) 0.67 |
| Didanosine (ddI) | -0.16 (0.16) 0.32 | -0.19 (0.15) 0.21 | -0.01 (0.14) 0.97 | 0.13 (0.15) 0.39 |
| Emtricitabine (FTC) | -0.11 (0.20) 0.60 | 0.08 (0.20) 0.69 | -0.12 (0.19) 0.53 | -0.04 (0.19) 0.84 |
| Tenofovir (TDF) | -0.003 (0.18) 0.99 | 0.02 (0.17) 0.89 | -0.10 (0.17) 0.54 | 0.14 (0.17) 0.41 |
| Zidovudine (ZDV) | 0.19 (0.16) 0.24 | 0.26 (0.15) 0.096 | -0.37 (0.15) 0.011 | -0.13 (0.15) 0.38 |
|  |  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV) | -0.18 (0.16) 0.28 | -0.15 (0.16) 0.34 | 0.06 (0.15) 0.71 | -0.06 (0.15) 0.72 |
| Nevirapine (NVP) | -0.14 (0.24) 0.56 | 0.03 (0.23) 0.90 | -0.19 (0.23) 0.39 | 0.29 (0.23) 0.20 |
|  |  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV) | -0.83 (0.97) 0.39 | -0.71 (0.92) 0.45 | 0.44 (0.90) 0.63 | -0.78 (0.90) 0.39 |
| Atazanavir (ATV) | -0.11 (0.27) 0.68 | -0.11 (0.26) 0.68 | -0.16 (0.24) 0.50 | 0.22 (0.24) 0.36 |
| Darunavir (DRV) | -0.48 (0.41) 0.25 | -0.44 (0.39) 0.26 | -0.05 (0.36) 0.89 | 0.32 (0.36) 0.37 |
| Lopinavir (LPV/r) | 0.16 (0.15) 0.30 | -0.02 (0.14) 0.89 | -0.09 (0.14) 0.50 | 0.02 (0.14) 0.90 |
| Nelfinavir (NFV) | 0.16 (0.22) 0.46 | 0.27 (0.21) 0.19 | 0.04 (0.20) 0.86 | -0.08 (0.20) 0.68 |
| Ritonavir (RTV) | 0.34 (0.26) 0.20 | -0.02 (0.25) 0.95 | 0.19 (0.23) 0.41 | -0.02 (0.23) 0.93 |
| Saquinavir (SQV) | 0.003 (0.36) 0.99 | -0.03 (0.35) 0.92 | 0.11 (0.34) 0.76 | -0.23 (0.34) 0.50 |
|  |  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL) | -0.003 (0.26) 0.99 | 0.05 (0.25) 0.85 | -0.02 (0.24) 0.95 | -0.02 (0.24) 0.94 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.

**Supplemental Table 5.** Association of Cumulative Duration of Individual ARVs with Primary LV Structure Measures in Models Mutually Adjusting for all Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART Drug(Duration in years)** | **LV Massest.1 (se) p-value** | **ED Dimensionest.1 (se) p-value** | **ED Wall Thicknessest.1 (se) p-value** | **ES Wall Stressest.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC)  | -0.02 (0.02) 0.40 | 0.00 (0.02) 1.00 | -0.01 (0.02) 0.79 | -0.01 (0.02) 0.59 |
| Abacavir (ABC)  | 0.01 (0.02) 0.70 | -0.01 (0.03) 0.79 | 0.04 (0.02) 0.090 | 0.02 (0.03) 0.42 |
| Stavudine (d4T)  | -0.002 (0.02) 0.90 | -0.02 (0.02) 0.45 | -0.02 (0.02) 0.27 | 0.05 (0.03) 0.073 |
| Didanosine (ddI)  | -0.01 (0.02) 0.46 | 0.01 (0.02) 0.52 | 0.01 (0.02) 0.60 | -0.02 (0.02) 0.48 |
| Emtricitabine (FTC)  | 0.04 (0.04) 0.40 | -0.02 (0.05) 0.63 | -0.03 (0.04) 0.51 | -0.13 (0.07) 0.088 |
| Tenofovir (TDF)  | -0.06 (0.04) 0.17 | -0.02 (0.05) 0.66 | 0.03 (0.04) 0.49 | -0.02 (0.06) 0.67 |
| Zidovudine (ZDV)  | 0.02 (0.02) 0.31 | 0.01 (0.02) 0.49 | -0.03 (0.02) 0.16 | 0.05 (0.02) 0.030 |
|  |  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV)  | -0.03 (0.02) 0.18 | -0.01 (0.02) 0.79 | -0.02 (0.02) 0.34 | -0.05 (0.03) 0.12 |
| Nevirapine (NVP)  | 0.02 (0.02) 0.36 | 0.04 (0.02) 0.13 | -0.01 (0.02) 0.59 | 0.05 (0.03) 0.051 |
|  |  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV)  | 0.03 (0.07) 0.63 | 0.06 (0.07) 0.37 | 0.09 (0.06) 0.15 | -0.13 (0.09) 0.13 |
| Atazanavir (ATV)  | 0.01 (0.06) 0.84 | 0.01 (0.06) 0.93 | 0.09 (0.06) 0.11 | 0.001 (0.07) 0.98 |
| Darunavir (DRV)  | -0.12 (0.20) 0.53 | -0.06 (0.20) 0.78 | -0.14 (0.18) 0.43 | 0.21 (0.22) 0.34 |
| Indinavir (IDV)  | -0.14 (0.07) 0.050 | -0.07 (0.08) 0.32 | -0.11 (0.07) 0.11 | -0.06 (0.10) 0.58 |
| Lopinavir (LPV/r)  | 0.02 (0.03) 0.58 | -0.003 (0.03) 0.91 | -0.02 (0.03) 0.49 | 0.02 (0.04) 0.67 |
| Nelfinavir (NFV)  | 0.02 (0.02) 0.28 | -0.01 (0.02) 0.65 | 0.02 (0.02) 0.19 | -0.01 (0.02) 0.53 |
| Ritonavir (RTV)  | 0.01 (0.02) 0.55 | 0.01 (0.02) 0.69 | 0.025 (0.02) 0.22 | -0.05 (0.03) 0.13 |
| Saquinavir (SQV)  | -0.00 (0.04) 1.00 | 0.00 (0.04) 0.99 | -0.058 (0.04) 0.10 | 0.03 (0.05) 0.52 |
|  |  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL)  | 0.24 (0.25) 0.34 | -0.20 (0.27) 0.46 | -0.30 (0.24) 0.21 | 0.49 (0.28) 0.084 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.

**Supplemental Table 6.** Association of Cumulative Duration of Individual ARVs with Secondary LV Structure Measures in Models Mutually Adjusting for all Other ARVs

|  | **Echocardiogram parameter Z-score** |
| --- | --- |
| **ART Drug(Duration in years)** | **ED Volumeest.1 (se) p-value** | **ES Volumeest.1 (se) p-value** | **Thickness-to-Dimension Ratioest.1 (se) p-value** | **ED Septal Thicknessest.1 (se) p-value** |
| *ART Drug Class: NRTIs* |
| Lamivudine (3TC)  | -0.03 (0.02) 0.16 | -0.02 (0.02) 0.34 | -0.01 (0.02) 0.69 | -0.002 (0.02) 0.91 |
| Abacavir (ABC)  | 0.02 (0.02) 0.28 | 0.03 (0.02) 0.15 | 0.01 (0.02) 0.75 | 0.01 (0.02) 0.54 |
| Stavudine (d4T)  | -0.01 (0.02) 0.54 | 0.01 (0.02) 0.67 | -0.02 (0.02) 0.26 | -0.02 (0.02) 0.28 |
| Didanosine (ddI)  | -0.01 (0.02) 0.44 | -0.01 (0.02) 0.55 | 0.000 (0.02) 0.99 | 0.01 (0.02) 0.48 |
| Emtricitabine (FTC)  | 0.01 (0.04) 0.74 | 0.01 (0.04) 0.83 | 0.003 (0.04) 0.94 | -0.06 (0.04) 0.14 |
| Tenofovir (TDF)  | 0.01 (0.04) 0.86 | 0.01 (0.04) 0.74 | -0.01 (0.04) 0.73 | 0.02 (0.04) 0.66 |
| Zidovudine (ZDV)  | 0.02 (0.02) 0.42 | 0.04 (0.02) 0.047 | -0.03 (0.02) 0.055 | -0.01 (0.02) 0.67 |
|  |  |  |  |  |
| *ART Drug Class: NNRTIs* |
| Efavirenz (EFV)  | -0.01 (0.02) 0.82 | -0.02 (0.02) 0.30 | 0.01 (0.02) 0.60 | -0.01 (0.02) 0.56 |
| Nevirapine (NVP)  | -0.003 (0.02) 0.89 | 0.004 (0.02) 0.86 | -0.01 (0.02) 0.81 | -0.02 (0.02) 0.32 |
|  |  |  |  |  |
| *ART Drug Class: PIs* |
| Amprenavir (APV)  | 0.001 (0.07) 0.99 | 0.02 (0.07) 0.73 | -0.01 (0.06) 0.86 | -0.04 (0.06) 0.46 |
| Atazanavir (ATV)  | 0.05 (0.06) 0.39 | 0.04 (0.05) 0.51 | -0.004 (0.05) 0.94 | 0.05 (0.05) 0.29 |
| Darunavir (DRV)  | -0.17 (0.20) 0.39 | -0.16 (0.19) 0.40 | -0.003 (0.17) 0.98 | 0.07 (0.17) 0.65 |
| Indinavir (IDV)  | -0.10 (0.07) 0.15 | -0.06 (0.07) 0.33 | 0.02 (0.06) 0.81 | -0.06 (0.06) 0.37 |
| Lopinavir (LPV/r)  | -0.002 (0.03) 0.95 | -0.01 (0.03) 0.82 | 0.003 (0.02) 0.89 | 0.002 (0.02) 0.92 |
| Nelfinavir (NFV)  | 0.02 (0.02) 0.23 | 0.01 (0.02) 0.61 | 0.02 (0.02) 0.31 | -0.004 (0.02) 0.78 |
| Ritonavir (RTV)  | 0.02 (0.02) 0.49 | -0.01 (0.02) 0.68 | 0.01 (0.02) 0.70 | 0.02 (0.02) 0.27 |
| Saquinavir (SQV)  | -0.01 (0.04) 0.75 | -0.01 (0.04) 0.87 | -0.04 (0.03) 0.28 | -0.10 (0.03) 0.004 |
|  |  |  |  |  |
| *ART Drug Class: Other* |
| Raltegravir (RAL)  | -0.05 (0.24) 0.85 | 0.07 (0.23) 0.78 | -0.07 (0.23) 0.75 | -0.52 (0.22) 0.018 |

Abbreviations: ART-antiretroviral treatment; NNRTI-non-nucleoside reverse transcriptase inhibitor; NRTI-nucleoside reverse transcriptase inhibitor; PI-protease inhibitor.

1 Parameter estimates based on a linear regression model including all individual ARVs shown, and adjusting for age and BMI Z-score at echocardiogram, sex, race, and ethnicity.